Early Phase III data suggest C5 complement inhibition may alter disease course in IgAN In a recent press release, AstraZeneca reported that Ultomiris (ravulizumab) has
Yoga is often celebrated for its ability to help people find their “zen,” but new research shows it might be doing some heavy lifting for
AskBio Inc., a gene therapy subsidiary of pharmaceutical giant Bayer AG, has taken a significant step forward in advancing treatment options for Parkinson’s disease. According
For nearly two decades, I’ve been building and maintaining a global online community for individuals and families affected by Moebius syndrome, a rare neurological condition
Fernando Mendoza’s journey to becoming the Las Vegas Raiders’ first overall NFL Draft pick is not a typical underdog narrative, it’s a testament to resilience,
Editor’s Note: Patient Worthy is honored to share this piece from our friends at Elephants & Tea, originally written by Katie Newbaum. To see the
As reported on NBC News, an ophthalmologist with a history of criticizing the U.S. government’s Covid-19 vaccine strategy is emerging as a leading contender to
My name is Maha, and I had the privilege of being my father’s — my Baba’s — caregiver. I’ll be blunt; it was tough. When
Johnson & Johnson announced promising long-term efficacy and safety data for Icotyde (icotrokinra), the first and only targeted oral peptide that precisely blocks the IL-23
As reported on PharmaBiz, Roche has secured CE mark approval for its Elecsys Neurofilament Light Chain (NfL) assay, a blood-based test designed to help detect
Astrocytoma and glioblastoma are fast-growing brain cancers that often return after surgery, with survival for astrocytoma patients averaging only four to five months. While medications
Lynk Pharmaceuticals announced a significant development in its pipeline with the China National Medical Products Administration (NMPA) formally accepting the New Drug Application (NDA) for
I’ve always been a nature lover. I like nothing better than going for a hike in the woods or strolling along the beach or gazing
Editor’s Note: Patient Worthy is honored to share this submission by Regina Portnoy, a clinical researcher with 20 years of experience working alongside patients. Many
Daiichi Sankyo and Merck announced a significant regulatory milestone with the FDA’s acceptance and Priority Review of ifinatamab deruxtecan (I-DXd), a potentially first-in-class therapeutic targeting
As reported on BioPharmaDive, Roche is restarting efforts to get Elevidys, a gene therapy for Duchenne muscular dystrophy (DMD), approved in Europe by launching a
I’ve always been an overachiever – someone who puts their mind to something and delivers more than was expected, someone who strives for greatness. I
IDEAYA Biosciences and Servier announced promising Phase 2/3 trial results for darovasertib, a selective PKC inhibitor, combined with crizotinib in the treatment of metastatic uveal
Cure GRIN Foundation @Lundbeck #raredisease
#developmental and Epileptic Encephalopathies (DEE)Calling all families! Did you know that GRI Disorders are classified as a Developmental and Epileptic Encephalopathies (DEE)? Don't miss out on this new opportunity!
Lundbeck is hosting a 1 hour, virtual webinar for families and caregivers navigating severe and rare developmental epilepsies, often referred to as Developmental and Epileptic Encephalopathy (DEE). This session will provide information about DEE and Lundbeck’s ongoing clinical research efforts in this space, including:
An overview of DEE
Overview of ongoing, actively enrolling Phase 3 clinical studies
Responses to frequently asked questions
For more information about this event, please reach out to [email protected].
Register Now: zoom.us/webinar/register/WN_ceq3_KCVTW6qhuqCkhQmxQ
DONATE BLOOD #OneBlood🚨 Please share this post to get the word out!
There is an 𝗨𝗿𝗴𝗲𝗻𝘁 𝗡𝗲𝗲𝗱 for 𝗮𝗹𝗹 𝗯𝗹𝗼𝗼𝗱 𝘁𝘆𝗽𝗲𝘀 𝗮𝗻𝗱 𝗽𝗹𝗮𝘁𝗲𝗹𝗲𝘁𝘀! Patients in hospitals are relying on your donations to fight their toughest battles.
We are open seven days a week. Your act today can make an impact tomorrow! Click to find a Big Red Bus or OneBlood Donor Center near you: oneblood.io/YzgYH
Myasthenia Gravis AssociationMay Virtual Monthly Meet-Up: Cell Therapy in MG with Dr. Dimachkie
💻 Our Virtual Monthly Meet-Up is Happening One Week Earlier This Month! 💻
Due to the Memorial Day holiday the following week, our May Virtual Meet-Up will take place early:
📅 Monday, May 18, 2026
⏰ 6:30-7:30 PM CT
🧠 Topic: Cell Therapy in MG: What Have We Learned?
Join us as we welcome Mazen Dimachkie, MD, FAAN, FANA from the University of Kansas Medical Center for an important discussion exploring the current status of cell therapy in Myasthenia Gravis.
Dr. Dimachkie is a nationally and internationally recognized clinician, educator, and researcher specializing in neuromuscular medicine and neurological discoveries.
📌 Registration Reminder:
To register, you must sign into your Zoom account or sign up for a free Zoom account before registering for the webinar.
Register Here: us02web.zoom.us/webinar/register/WN_JF-R1jGgTcebxMtbITYyhA
We hope you’ll join us for this informative conversation and community connection!
#MyastheniaGravis #MGCommunity #VirtualMeetUp #NeuromuscularResearch #CellTherapy #careaboutrare #rarekc #mgstrong #ihaveheardofmg #mgawareness #neuromuscular #autoimmune #myastheniagravis #worldwithoutmg #mga5k #mgatriplecrownshowdown #mgarun #missouricure
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
